Short Interest in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Increases By 8.0%

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 15th total of 5,120,000 shares. Based on an average daily volume of 831,700 shares, the short-interest ratio is presently 6.6 days. Currently, 10.0% of the company’s shares are sold short.

Analysts Set New Price Targets

Several brokerages have commented on AGIO. StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $60.00 to $56.00 in a research report on Friday, September 27th. Scotiabank boosted their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Leerink Partnrs cut shares of Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, Agios Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Stock Up 1.9 %

AGIO traded up $0.60 during midday trading on Friday, hitting $32.42. The company had a trading volume of 807,528 shares, compared to its average volume of 953,064. The stock’s 50 day moving average price is $44.72 and its 200 day moving average price is $45.07. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The company has a market capitalization of $1.85 billion, a price-to-earnings ratio of 2.85 and a beta of 0.87.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the second quarter valued at $37,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the last quarter. Quest Partners LLC increased its holdings in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after purchasing an additional 1,283 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in Agios Pharmaceuticals during the 3rd quarter worth $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.